What Desyncra Technologies does

Desyncra Technologies Limited is a UK-incorporated private medical technology company founded in 2015 that has developed CR® Neuromodulation, a proprietary acoustic therapy targeting chronic tinnitus. The technology works by delivering patient-specific therapeutic tones via a customized iPod device with custom-designed earphones, using a proprietary pitch-matching procedure to disrupt hyperactivity in tinnitus neuronal networks. Treatment spans a 36-week protocol with periodic optimization at 3, 8, 12, 24, and 36 weeks, and clinical evidence indicates that symptom reductions persist beyond the active therapy period as neuronal networks adapt. The platform has documented applicability potential to Parkinson's disease, epilepsy, and migraine, though tinnitus is the only commercialized indication today.

Desyncra for Tinnitus has secured FDA clearance in the United States and CE Mark certification in Europe, and is offered exclusively through a network of over 70 authorized audiology and ENT clinics in the US and Europe (Germany, UK, Switzerland, Austria, Belgium, Netherlands, Poland, Spain, France). The company does not sell directly to patients; instead, it provides the technology and customized devices to certified healthcare providers. International operations outside the UK are handled through a wholly-owned German subsidiary, Desyncra Operating GmbH. Distribution is supported by a Clinic Finder digital tool and a multi-language website (English, German, French, Spanish).

The business model combines technology licensing and hardware provision (customized iPod devices with proprietary earphones) sold or licensed to clinical providers. Revenue is generated per treatment course rather than through subscription or recurring SaaS contracts. The evidence base comprises five clinical studies covering 486+ patients across the UK, Germany, and Hungary, with publications in peer-reviewed journals including Frontiers in Neurology, BioMed Research International, Restorative Neurology and Neuroscience, and Ideggyogyaszati Szemle. Academic research partnerships include Stanford University, Veterans Affairs Portland, and centers in England and Germany.

Name

Desyncra Technologies

Legal name

Desyncra Technologies Limited

Website

https://desyncra.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Desyncra Technologies is a UK-based medical technology company that has developed CR® Neuromodulation, an FDA-cleared, CE-marked acoustic therapy for chronic tinnitus delivered through a network of over 70 authorized audiology and ENT clinics across the US and Europe via a customized iPod device.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Non-prescription / OTC Digital Therapeutics (HLACANAC)

Keywords

• Neuromodulation therapy
• Tinnitus treatment
• Acoustic stimulation
• Medical device technology
• Neurological therapy

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Medical Device Technology Licensing: Desyncra develops and provides CR® Neuromodulation technology to healthcare providers (audiologists, ENT clinics). The company is described as a technology developer and provider, with products distributed through authorized clinics rather than directly to patients.
2. Clinic Network Distribution: Distribution of therapy systems through a network of over 70 authorized clinics across the United States and internationally (Germany, UK, Switzerland, Austria, Belgium, Netherlands, Poland, Spain, France).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Desyncra develops and supplies Desyncra™ for Tinnitus, a neuroscientific CR® Neuromodulation therapy that uses acoustic stimulation to disrupt hyperactivity in tinnitus neuronal networks. The therapy is delivered through customized iPod devices with custom-designed earphones over a 36-week treatment course, with therapeutic tones personalized to each patient via a proprietary pitch-matching procedure. The product carries FDA clearance and CE Mark and is distributed exclusively through authorized audiology and ENT clinics rather than sold directly to patients.

Product overview

Desyncra Technologies offers a single core product: Desyncra™ for Tinnitus, a neuroscientific therapy that applies CR® Neuromodulation to disrupt and desynchronize hyperactivity in tinnitus neuronal networks. The therapy is delivered via a customized iPod device with custom-designed earphones, with therapeutic tones tailored to each patient's exact tinnitus profile. The treatment spans 36 weeks with periodic optimization visits at 3, 8, 12, 24, and 36 weeks. The technology platform also shows potential for other neurological conditions including Parkinson's disease, epilepsy, and migraine.

Differentiator

Problem solved

Functional benefit

Products and services

• Desyncra™ for Tinnitus A 36-week acoustic neuromodulation therapy system that delivers CR® Neuromodulation via customized iPod devices and proprietary earphones, with therapeutic tones personalized to each tinnitus patient's exact pitch profile through a proprietary pitch-matching procedure. Provided to clinics for use with chronic tinnitus patients experiencing distressing loudness and annoyance.

Quantifiable outcome

• Over 3,000 tinnitus patients treated successfully
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Stanford UniversitycoreStrategic or Co-development PartnerAcademic research partnership for CR® Neuromodulation clinical research, contributing to the company's evidence base and scientific validation.
• Veterans Affairs PortlandcoreStrategic or Co-development PartnerClinical research partnership contributing to the company's portfolio of peer-reviewed clinical studies on tinnitus treatment.
• Research Centers in England and GermanycoreStrategic or Co-development PartnerInternational clinical research partnerships supporting multi-site clinical studies and European regulatory approvals (CE Mark).

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• MicroTransponder: US-based developer of paired vagus-nerve-stimulation therapy (Vivistim and SerenePath) targeting tinnitus and stroke-related indications; an early-stage neuromodulation peer with overlapping clinical-mechanism ambitions for tinnitus.
• Oto (formerly Oto Health): Digital/app-delivered tinnitus therapy (CBT-based) targeting the same patient population via direct-to-consumer and audiologist channels; competes for the underserved chronic-tinnitus segment Desyncra addresses.
• Sound Relief Hearing Center: US audiology clinic network specializing in tinnitus treatment; comparable as both an authorized Desyncra provider and a competitor channel offering alternative tinnitus therapies (CBT-based and sound-based) to similar patient cohorts.

Broad incumbents

• Cochlear Limited: Global implantable hearing-solutions company (cochlear implants, bone-conduction systems); adjacent incumbent in the same neuro-otology and ENT prescribing channel as Desyncra's therapy.
• GN Hearing (ReSound): Hearing-aid manufacturer (parent of ReSound and Beltone) with a ReSound Relief tinnitus app and integrated tinnitus therapy features, serving the same audiologist distribution channel that Desyncra targets.
• Sonova (Phonak): Swiss parent of Phonak and other hearing-aid brands offering tinnitus therapy features inside hearing aids; a broad incumbent whose products sit alongside CR® in audiologists' tinnitus recommendation set.
• Widex: Major hearing-aid manufacturer offering the Widex Zen tinnitus therapy/sound therapy program integrated into its hearing aids; competes for the same audiologist-channel tinnitus patient and shares Desyncra's positioning as an evidence-led therapy.
• Signia (WS Audiology): Global hearing-aid brand with a dedicated tinnitus therapy feature set (Notch Therapy, built-in tinnitus notch) bundled with its core hearing-aid portfolio, offering ENT/audiology clinics an incumbent alternative to a standalone neuromodulation therapy.
• Oticon: Hearing-aid incumbent with a Tinnitus SoundSupport offering and clinical-evidence-heavy go-to-market through audiologists; competes for the same audiology-channel prescribing decision as Desyncra's CR® therapy.

Direct peers

• Neuromod Devices: Ireland-based developer of Lenire, a bimodal (auditory + tongue) neuromodulation device FDA-cleared for tinnitus — the closest head-to-head competitor to Desyncra's CR® Neuromodulation, with a comparable clinic-distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/desyncra

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Desyncra Technologies